The Austria-based biotech company is working on the vaccine in conjunction with the Institut Pasteur in France. The research institute holds extensive rights to the new vaccine through a licensing deal with the company.
The Zika vaccine is based on previous technology the biotech used to make a measles vaccine.
Erich Tauber, MD, CEO of Themis Bioscience, says the vaccine’s development will benefit from the technology’s proven track record for immunizing against measles.
More articles on supply chain:
Medtronic invests $20M in Mazor Robotics
FDA panel endorses Amgen’s biosimilar version of Humira
GE stakes claim on cell therapy market with Biosafe acquisition
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
